menu
    • menu
    [{"orgOrder":0,"company":"Trawsfynydd Therapeutics","sponsor":"Traws Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"83-0060","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Trawsfynydd Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trawsfynydd Therapeutics \/ Trawsfynydd Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Trawsfynydd Therapeutics \/ Trawsfynydd Therapeutics"},{"orgOrder":0,"company":"Trawsfynydd Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Travatrelvir","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Trawsfynydd Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trawsfynydd Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Trawsfynydd Therapeutics \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Trawsfynydd Therapeutics

    Menu

    Trawsfynydd Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Trawsfynydd Therapeutics

                            U.S.A arrow
                            ISPOR Europe 2025
                            Not Confirmed

                            Trawsfynydd Therapeutics

                            U.S.A arrow
                            ISPOR Europe 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 83-0060

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Recipient : Traws Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of 83-0060 in Hea...

                            Details : 83-0060 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            May 07, 2024

                            Lead Product(s) : 83-0060

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Recipient : Traws Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Trawsfynydd Therapeutics

                            U.S.A arrow
                            ISPOR Europe 2025
                            Not Confirmed

                            Trawsfynydd Therapeutics

                            U.S.A arrow
                            ISPOR Europe 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Travatrelvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Trawsfynydd Gets Approval for TRX01 Patient Trial, a COVID-19 Protease Inhibitor

                            Details : TRX01(travatrelvir) is an inhibitor targeting the SARS-CoV-2 viral main protease (MPro/3CL). It is being developed for the treatment of Covid 19.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 12, 2024

                            Lead Product(s) : Travatrelvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth